Related Experiment Video

Updated: Mar 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a)

Marija Vavlukis1, Kristina Mladenovska2, Arlinda Daka3

  • 1Ss Cyril and Methodius University, Skopje, Republic of Macedonia marija.vavlukis@gmail.com.

The Annals of Pharmacotherapy
|June 1, 2016
PubMed

Insights

Rosuvastatin significantly reduced elevated lipoprotein(a) [Lp(a)] more than atorvastatin. Adding fenofibrate or extended-release niacin to atorvastatin also improved Lp(a) reduction without adverse effects.

Area of Science:

  • Cardiology
  • Pharmacology
  • Lipid Metabolism

Background:

  • Limited evidence exists on the effectiveness of various lipid-lowering agents in reducing elevated lipoprotein(a) [Lp(a)].
  • Elevated Lp(a) is a significant risk factor for cardiovascular disease.

Purpose of the Study:

  • To compare the therapeutic efficacy and safety of different lipid-lowering strategies on elevated Lp(a) levels.
  • To evaluate rosuvastatin, atorvastatin, atorvastatin with fenofibrate, and atorvastatin with extended-release niacin.

Main Methods:

  • A prospective interventional study involving 87 patients with coronary artery disease (CAD) or high CAD risk and Lp(a) >50 mg/dL.
  • Comparative analysis of Lp(a), lipid profiles, and safety markers across four treatment groups over six months.
  • Treatments included rosuvastatin 40 mg, atorvastatin 80 mg, atorvastatin 40 mg + micronized fenofibrate, and atorvastatin 40 mg + 1g extended-release niacin.

Main Results:

  • All treatment groups showed significant reductions in lipid fractions after six months.
  • Rosuvastatin and combination therapies (atorvastatin + fenofibrate or niacin) demonstrated greater Lp(a) reduction compared to atorvastatin alone.
  • No adverse effects were reported in any treatment group, indicating good safety profiles.

Conclusions:

  • Rosuvastatin appears more effective than atorvastatin in decreasing Lp(a) levels.
  • Combination therapy with fenofibrate or extended-release niacin can enhance the efficacy of atorvastatin in managing elevated Lp(a).
  • These findings suggest potential therapeutic benefits of specific statin regimens and add-on therapies for patients with elevated Lp(a).
Abstract

Keywords:
dyslipidemiaextended-release niacin (ERN)lipoprotein (a)micronized fenofibratestatins

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
569
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
835
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
783
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75